Ambalal Sarabhai Enterprises Ltd. (BSE: 500009) is a Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹292 Cr, it ranks #2,363 by market cap among the 6,137 Indian listed companies on FinBizNet, and #32 of 63 in Pharmaceuticals. At ₹34.65 (as of 25 Oct 2026), the share price is 30.7% below its 52-week high of ₹49.98 and 14.9% above its 52-week low of ₹30.15. The share price is down 9.0% over one year and up 7.0% over three months.
| Current Price | ₹34.65 |
|---|---|
| Market Cap | ₹292 Cr |
| BSE Code | 500009 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 16.5 |
| Return on Equity | 11.94% |
| Return on Assets | 4.30% |
| 52-Week Range | ₹30.15 – ₹49.98 |
| 1-Year Price Change | -9.0% |
| 3-Month Price Change | +7.0% |
| Beta (1Y) | 0.87 |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.ase.life |
Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company offers products for oncology, infertility, and uro-gynaec areas; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients. It also provides broadcast and professional video/audio, and electronic products. Ambalal Sarabhai Enterprises Limited was incorporated in 1977 and is based in Ahmedabad, India.
1. Pharmaceuticals-This segment manufactures, markets, and supplies pharmaceutical products. 2. Electronics-This segment offers analytical, test, and measuring instruments. 3. Unallocable-0 4. Segment Adjustment-0
1. Pharmaceuticals-54.6% 2. Electronics-45.4%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Ambalal Sarabhai Enterprises Ltd. | ₹292 Cr | 16.5 | 11.94% | — | -9.0% |
Listed by market capitalisation. Ratios are shown for context only.
Ambalal Sarabhai Enterprises Ltd. is trading at ₹34.65, with a market capitalisation of ₹292 Cr.
Ambalal Sarabhai Enterprises Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Ambalal Sarabhai Enterprises Ltd. has a P/E of 16.5 and a return on equity of 11.94%.
Ambalal Sarabhai Enterprises Ltd. is listed on the BSE under the scrip code 500009.
Ambalal Sarabhai Enterprises Ltd.'s share price is down 9.0% over one year and up 7.0% over three months. Its 52-week range is ₹30.15 to ₹49.98.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.